Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356575 | 1.00 | ALDH1A1 (0.39) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL29415489 | 0.97 | HDAC1 (0.40) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL3490800 | 0.97 | HDAC1 (0.40) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL10340282 | 0.95 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL154742 | 0.95 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL29379500 | 0.95 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL29352062 | 0.93 | ALDH1A1 (0.44) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL42368 | 0.93 | ALDH1A1 (0.44) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL17072458 | 0.88 | HDAC1 (0.35) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL20983700 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2449 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260034253-A1 | NECTIN-4 MINIPROTEIN CONJUGATES | AKTIS ONCOLOGY INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | claimed |
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | ANGIEX, INC. (US) | 2025-09-30 | — | — | US | claimed |
| WO-2025151464-A1 | ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4580684-A1 | DRUG CONJUGATES OF HUMANIZED ANTI PVR ANTIBODIES | Nectin Therapeutics Ltd. (IL) | 2025-07-09 | — | — | EP | claimed |
| EP-4551255-A2 | NECTIN-4 MINIPROTEIN CONJUGATES | Aktis Oncology, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | claimed |
| US-20250009890-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. | 2025-01-09 | — | — | US | claimed |
| WO-2011106528-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| WO-2011100398-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
| US-20110171125-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-14 | — | — | US | claimed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | claimed |
| US-20100330081-A1 | CRIPTO BINDING MOLECULES | BIOGEN IDEC MA INC. (US) | 2010-12-30 | — | — | US | claimed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | claimed |
| EP-2162152-A2 | CRIPTO BINDING MOLECULES | Biogen Idec MA, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| WO-2008150530-A2 | CRIPTO BINDING MOLECULES | BIOGEN IDEC MA INC. (US) | 2008-12-11 | — | — | WO | claimed |